Bowling Portfolio Management LLC lifted its position in Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Rating) by 19.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,253 shares of the company’s stock after buying an additional 3,615 shares during the period. Bowling Portfolio Management LLC’s holdings in Amneal Pharmaceuticals were worth $93,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMRX. Allspring Global Investments Holdings LLC bought a new position in Amneal Pharmaceuticals during the 4th quarter worth about $2,144,000. Dimensional Fund Advisors LP increased its holdings in Amneal Pharmaceuticals by 12.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,515,021 shares of the company’s stock worth $7,258,000 after purchasing an additional 172,629 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its holdings in Amneal Pharmaceuticals by 55.1% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 8,388 shares of the company’s stock worth $41,000 after purchasing an additional 2,979 shares in the last quarter. Teacher Retirement System of Texas increased its holdings in Amneal Pharmaceuticals by 20.3% during the 4th quarter. Teacher Retirement System of Texas now owns 18,632 shares of the company’s stock worth $89,000 after purchasing an additional 3,145 shares in the last quarter. Finally, Hedges Asset Management LLC bought a new position in Amneal Pharmaceuticals during the 4th quarter worth about $359,000. Institutional investors and hedge funds own 38.54% of the company’s stock.
Separately, Barclays lowered their target price on Amneal Pharmaceuticals from $8.00 to $7.00 in a report on Thursday, April 28th.
Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) last announced its quarterly earnings data on Wednesday, May 4th. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.01). The company had revenue of $497.30 million during the quarter, compared to the consensus estimate of $502.29 million. Amneal Pharmaceuticals had a net margin of 0.68% and a return on equity of 61.08%. Amneal Pharmaceuticals’s revenue was up .9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.19 EPS. On average, analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.8 earnings per share for the current fiscal year.
Amneal Pharmaceuticals Company Profile (Get Rating)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
- Get a free copy of the StockNews.com research report on Amneal Pharmaceuticals (AMRX)
- Victoria’s Secret Stock is Out of the Box
- Downturn Gives These 3 Buys Juicy Dividend Yields
- Time For a Ride in Six Flags Stock
- Why Dollar General (NYSE: DG) Should Be In Your Portfolio
- Korn Ferry Is A Good Buy For The Recession And Beyond
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.